- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Budenheim 
Captisol 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
KLK Oleo 
Lipoid 
Dr. Paul Lohmann 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Budenheim Captisol Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IOI Oleo Ingredient Pharm JRS Pharma KLK Oleo Lipoid Dr. Paul Lohmann Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma
Rapidly dissolving microneedle patch embedded with long-acting microspheres for sustained release of goserelin
Rapidly dissolving microneedle patch embedded with long-acting microspheres for sustained release of goserelin
Abstract
Goserelin is widely employed as a form of androgen deprivation therapy in the management of prostate cancer. Given the chronic nature of hormonal therapy, sustained and long-term drug administration is essential to ensure therapeutic efficacy. Goserelin is often formulated as sustained-release implants or microspheres requiring intramuscular injections.
Highlights
- A rapidly dissolving microneedle patch is developed for transdermal long-acting microsphere delivery.
- Local miniature drug reservoirs mediated by microneedles enable sustained drug release for at least four weeks.
- Transdermal microneedle patch achieves comparable PK behavior to intramuscular administration.
- Minimally invasive administration for desired biocompatibility and improved patient compliance.
Both delivery methods necessitate administration by trained healthcare personnel and are frequently associated with poor patient compliance due to procedural invasiveness and considerable discomfort. Herein, we developed a goserelin microsphere-loaded microneedle (GSR-MN) patch as a minimally invasive alternative. The microneedles exhibit robust mechanical strength and rapid dissolution properties, enabling them to effectively penetrate the stratum corneum and facilitate the delivery of goserelin microspheres into the underlying skin tissue.
The GSR-MN patch demonstrates excellent biocompatibility and biosafety, and is capable of sustaining goserelin release over a 28-day period. The therapeutic outcomes were comparable to those of conventional intramuscular goserelin microsphere administration, offering a promising strategy to improve patient adherence and reduce treatment-associated discomfort.
Continue reading here
Materials
All materials were purchased from Aladdin unless otherwise specified. HA was purchased from Bloomage. PVP was purchased from TCI Shanghai. PBS was purchased from Biosharp. GSR-MSs were supplied by Luye Pharma.
Quanquan Han, Yunlong Jiao, Ruisi Cai, Jiahuan You, Xiaofeng Chen, Wentao Zhang, Hao Wang, Huimin Ji, Xinmin Yu, Yinuo Xu, Fenghua Fu, Xuemei Zhang, Jicheng Yu, Yuqi Zhang, Zhen Gu, Rapidly dissolving microneedle patch embedded with long-acting microspheres for sustained release of goserelin, Journal of Controlled Release, 2025, 114397, ISSN 0168-3659, https://doi.org/10.1016/j.jconrel.2025.114397.
Read also our interesting article:
Efficient transdermal drug delivery via a lance-microneedle delivery system with thumb force application
Enjoy the video collection from the CPHI Frankfurt 2025:
